Details for Patent: 7,229,630
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,229,630 protect, and when does it expire?
Patent 7,229,630 protects ORAVERSE and is included in one NDA.
This patent has sixteen patent family members in twelve countries.
Summary for Patent: 7,229,630
| Title: | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
| Abstract: | The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist. |
| Inventor(s): | Chen; Andrew X. (San Diego, CA), Knowles; Julius (Del Mar, CA), Weber; Eckard (San Diego, CA) |
| Assignee: | Novalar Pharmaceuticals, Inc. (DE) |
| Application Number: | 10/465,810 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Use; Dosage form; Composition; Device; |
Recent additions to Drugs Protected by US Patent 7,229,630
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE | 022159 | May 9, 2008 | RX | Yes | See Plans and Pricing | Y | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 7,229,630
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,229,630
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2003247568 | See Plans and Pricing | |||
| Brazil | 0311965 | See Plans and Pricing | |||
| Brazil | PI0311965 | See Plans and Pricing | |||
| Canada | 2489526 | See Plans and Pricing | |||
| China | 100391460 | See Plans and Pricing | |||
| China | 1688312 | See Plans and Pricing | |||
| European Patent Office | 1539170 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
